The 7 major postoperative pain markets reached a value of US$ 2,615.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,456.0 Million by 2034, exhibiting a growth rate (CAGR) of 6.91% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2023 |
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 2,615.7 Million
|
Market Forecast in 2034
|
US$ 5,456.0 Million
|
Market Growth Rate 2024-2034
|
6.91%
|
The postoperative pain market has been comprehensively analyzed in IMARC’s new report titled “Postoperative Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Postoperative pain refers to the pain that a person experiences after a surgical procedure. It can vary in intensity and duration depending on the type and extent of the surgery. There are different types of postoperative pain: acute pain, chronic pain, phantom pain, and incisional pain. Acute pain occurs immediately after surgery and typically lasts for a few days to a couple of weeks. It is usually caused by surgical incisions, tissue trauma, and the healing process. On the other hand, chronic pain can persist for months or even years after surgery, particularly if the surgical procedure was a major one or if the patient had pre-existing chronic pain conditions. Phantom pain can occur after amputation or nerve damage; it is a sensation of pain that is felt in a limb or body part that is no longer present. Incisional pain is felt at the surgical incision site, caused by the incision itself and tissue trauma. Postoperative pain is a normal and expected part of the healing process and can be managed with appropriate pain management strategies and treatments. The treatment typically includes a combination of medication, physical therapy, and relaxation techniques. Medication options include over-the-counter pain relievers, such as ibuprofen, and prescription pain medication. Narcotics may be prescribed for severe pain. In addition to medication, physical therapy can help to manage pain and improve mobility, while relaxation techniques, such as deep breathing or meditation, can help to reduce stress and tension that can exacerbate pain.
The increasing prevalence of chronic diseases, the growing number of surgical procedures, and the rising cases of accidental injuries are primarily driving the global postoperative pain market. In addition to this, the escalating consumer awareness regarding palliative care coupled with the inflating demand for innovative and advanced pain-relaxing medications is further creating a positive outlook for the market. Moreover, the emerging popularity of orally administered drugs on account of their numerous associated benefits, including non-invasiveness, ease of use, self-administration, etc., is also propelling the market growth. Apart from this, several key players are focusing on the development of extended-release non-opioid drugs and abuse-deterrent opioid drugs for post-surgery pain management. This, in turn, is further acting as a significant growth-inducing factor. Additionally, the widespread adoption of non-pharmacological therapies, such as acupuncture, psychological approaches (cognitive behavioral therapy, mindfulness-based stress reduction), chiropractic manipulation, alternative medicine therapies, etc., is also augmenting the global market. Besides this, the ongoing development of new and innovative products and techniques, including nerve blocks and pumps that deliver pain medication directly to the surgical site, is further bolstering the market growth. Moreover, the increasing investments in R&D activities for high-quality postoperative management solutions due to the escalating demand for effective pain management with minimum side effects are expected to drive the global postoperative pain market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the postoperative pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for postoperative pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the postoperative pain market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current postoperative pain marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Xaracoll (Bupivacaine) | Innocoll |
Anjeso (Meloxicam injection) | Baudax Bio |
Omidria (Ketorolac/phenylephrine) | Omeros Corporation |
Naropin (Ropivacaine) | Astrazeneca |
Acular (Ketorolac ophthalmic) | AbbVie |
Tapentadol IR | Grunenthal |
Oxymorphone | Endo Pharmaceuticals |
Opiranserin | Vivozon |
Difelikefalin | Cara Therapeutics |
Celecoxib long-acting injectable | Arthritis Innovation Corporation/MedinCell |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Postoperative Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies